Text

Amend 12 to License 50-19913-01 for Ketchikan General Hosp, Amending License in Entirety
	ML20155H757
Person / Time
Site:	03019521
Issue date:	10/15/1987
From:	Riedlinger B; NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V)
To:	;
Shared Package
ML20155H761	List: ML20155H757; ML20155H786;
References
	50-19913-01, 50-19913-1, NUDOCS 8806200356
	Download: ML20155H757 (4)
	v • d • e

i

p = = y = = == = == == =-m mmmm m m m m m a m iim um m m m a mm m m m-immmm_mgm

mmm mg

I

l (NRe Form 374

1

4

g

PAGE

OF

PAGES

3 83)

U.S. NUCLEA.Q REGULATORY COMMISSION

l

MATERIALS LICENSE

Amendment flo.12

h

l

Code of Federal Regulations, Chapter I, Parts

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Pubhc L,aw 93-438), and Title 10,

g

30,31,32,33,34,35,40 and 70, and in reliance on statements and representations l

g

heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and

I

source, and special nuclear material designated below; to use such material for the purpose (s) and at the p

>

1

deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This !h

I

license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is lh

l

subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any

q conditions specified below.

p

" ' ' " ' "

In accordance with letter

II

dated September 25, 1987

)

its entirety to read as follow

l

50-19913-01 is amended in

i

1.

Ketchikan General Hospital

3. Licer.se number

g

!

i

lN

I

1

3100 Tongass Avenue

p

,

..

I

--

y .

u

. ; c

l'

4' Espira, tion date January 31, 1992

il

E

Ketchikan, Alaska 99901

.

-g

%

'

5. Docket or

-

q

'

030-19521

g

l

Reference No.

g

-

i

6. Byproduct, source, and/or

2,

7. Chemical and/or physical

i 8. Maximum amount that licensee

N

special nuclear material

A

form

6 may possess at any one time

f

i

9,

' ~

" under this license

!I

I

b

I

.-

u.

-

>

s

A.

Any byproduct material

A.

'Any radiopharmaceuticalf

l

A.eAsnecessaryforuses{

'

y

listed in Groups.I-and

listed in GroupsfI and II

' authorized in

g

II of Schedule A,y

o'f Schedule A, Section

c Subitem 9.A.

!g

i

10 CFR 35

L-

t

, -

C

.

p

i

Section 35.100 of %

35.-100 of'10 CFR 35:

'

_

e

,5

<

p

j.

,

-L_

.

,' o

lt

"

I

l

B.

Any byproduct material iB. '

Any fohn listedlin Group III' B., ~ 2 curies of each

lI

'

I

f' authorized inbyproduct mate

I

g

listed in Grcup III A

- " "of Schedule A,lSection 35.100

}

q

of Schedule A,

of 10;CFR 35 ;

'

,

7

.

l

Section 35.100 of

e

,.1

Subitem 6.B. 10

g

'

s

'

L

,1

I

CFR 35

.

3

'

,

~>

in

I

'

>

Any byproduct material'/

.

! 'C.

3millicuriesofeach!N

I

C.

'tc.,

Any

,

}p

l

listedinSection31.11(a))

{

byproduct material

l

g

of 10 CFR 31

authorized in

'

t

'

-

Subitem 6.F.

!p

q

i

't

I

D.

Xenon-133

D.

Gas or gas in solution

D.

50 millicuries

l'

l

that is the subject of

.

an active (i.e., not

y

I

withdrawn or terminated)

I

"flew Drug Application"

1

(hDA) approved by FDA or

,

I

an active (i.e., not

j

l

withdrawn, teminated or

'

g

on "clinical hold")

!

q

"flotice of Claimed

l

N

Investigational Exemption

'

I

for a flew Drug" (IND) that

l

has been accepted by FDA

>

i

!(

!

W

l

esosoo356 e71015

.,kg

1l.

REG 5 LIC30

."

U

iL_ . so-19913r L _PDR_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

o

(

^

p u mp m m m mm mam m === = == == mamm a m.mm mm mmmmm m e m a mm m m m mm mmm m m m mm9

l

NRC Form 374A

U.S. NUCLE AR R EOULATcRY COMMIS$10N

d

4

I

p,gg

g,

PAGES

""S'6ifg"y{301

!

'

g

-

l

MATERIALS LICENSE

y

4

SUPPLEMENTARY SHEET

NN.Ig[t1"

i

'

"

i

>

l

Amendment No. 12

N

>

I

h

I

6. BYPRODUCT, SOURCE, AND/0R

7. CHEMICAL AND/0R PHYSICAL

8. MAXIMUM AMOUNT THAT LICENSEE

I

SPECIAL NUCLEAR MATERIAL

FORM

MAY POSSESS AT ANY ONE TIME

B

UNDER THIS LICENSE

l

l,

,

q

E.

Phosphorus 32

E.

Any soluble phosphate

E.

10 millicuries

l

I

that has been manufactured,

y

a

labeled, packaged, and

B

4

distributed in accordance

>

l

with a specific license issued

l

g

pursuant to;Section 32.72 of

y

q

10 CFPJ32 op a specific license

p

q

\\, issued to a manufacturer,by an

i

4

- ./ Agreement State pursuant-to.

I

>

i

'

(

equivalentstateregulation{

>;

-

[

l

F.

Americium 241

F.

Sealed sources

q

.(AmershanAMC.24)

~F.

Not to exceed

,

14 millicuries

n

4

'e

'

per source

p

M

.

>

l

}! 9.

Authorized use

'

i

,

A.

Any diagnostic procedure 111sted in Grcups I and II of Schedule;A Section 35.100

l

'

g

,

q

of Title 10, Code',of Federal Regulations.:

~

n

'

-

g

'

!

,

p

4

,

.

i

B.

Preparation and use of radiopharmaceuiilcals;for any diagnostic procedure listed

b

in Group III of Schedule A, Section 35.#100;of-Title 10, Code of Federal

l

lj

g

Regulations.

-

p

i C.

-In vitro studies.

'

)

(

W

'

q

t

lD.

Blood flow and pulmonary function studies.

E.

For treatment of polycythenia vera, leukemia,a'nd bone metastases.

l

4

l

4 F.

Anatomical marker.

l d@4'

l

,

!

l

4

,4

%>

gl

l>

q

l>

q

>

E<

4

b

4

e

i>

f>E

4

l

.)

,

xrymr.r3ra.w g e wm e xaare m iru rw r w irmwrxrxrsrx2Wxrxrxr2

y

(.

r __ _ _ _ _ _ _ . --- _ r % unn -.~." ~ - ,

,. s w se n nens w m m w m . . . ,

l

NRC Form 3H A

-o , L a

iTORY COMMISSION

PAGE

OF

PAGES

l

$'6_"IN{3-01

!

'

l

'hN.YCf[2"1"

'

UP LE

F

!

5

l

Amendment No.12

l

h

I

b

!

CONDITIONS

N

I

N

!

10. Licensed material shall be used only at Ketchikan General Hospital, 3100

l

Tongass Avenue, Ketchikan, Alaska,

p-

lN

i

'

11. Licensed material listed in Item 6 above is authorized for use by, or under the

N.

i

supervision of, the following individual (s) for the materials and uses

N

I

indicated:

>-

I

R

l-

Zeke L. Hendricks, M.D.

.. 7

Groups I, If, and III

l

"

..

n-

In vitro < studies

y

!

'

Xenon 133' < ..

E

i

-

Phosphorus 32 as' soluble phosphate for

N

i

'

!

treatment of polycythemia vera,

E

l

leukemia, and bone metastases

l

j

-

Americtum 241 anatomical marker

jp

i

.

1

i

Arthur K. Harris, M;D.

Groups I, II,"and III

>

f

In vitro studies

O

>

'

. Xenon 133

>

i

'

Phorphorus:32 as soluble' phosphate for

f

l

'

i

}-

treatment of polycythemia vera,

p

'&.

_ leukemia, and bone metastases

>

'

i

-

Americium ~241' anatomical marker

n-

~

'

i

t;

!

,

l

John C. Jowett, M.D.;

Ghoups1,II,andIII

(

In vitro studies

p

'

i

Enon 133 .

. ,

y

Americium 241 anatomical marker

'

>!

l

.

i

Ij

d':

Stephen C. Tines, M.D.

Groups I, II, and III

l

!f

I

In vitro studies

$

Enon 133

I'

' Americium 241 anatomical marker

!)

i

>

h

12.. The Radiation Protection Officer for the activities authorized by this license

(i

!

is Dr. Zeke L. Hendricks.

13.

For a period not to exceed sixty (60) days in any calendar year, a visiting

I

9

physician is authorized to use licensed material for human use under the tems

)

d

of this license, provided the visiting physician:

[@i

?i

A.

Has the prior written permission of the hospital's Administrator and its

j

Radiation Safety Comittee, and

jpi

i>

B.

Is specifically named as a user on a Nuclear Regulatory Commission license

y

q

L

authorizing human use, and

> <

N

j

C.

Performs only those procedures which the physician is specifically

}

j

authorized to perform pursuant to a license issued by the Nuclear

lp

-;l

Regulatory Comission.

$

b

f

l

mm.mmm.m.mm.mm-,,.m.m,,.mmm.m.mmmmm,a

l

_

. .

.

..

_ _ .

__ ,_________

.__,

I

-

NIC Form 3N A

U.S. NUCLEAR REIULaTcRY COMMISSION

PAGE

OF

7 AGES _

l

"**"5Y) iib [3-01

l

'

l

MATERIALS LICENSE

h

po,g, , ,, g ,r,,,,,, ,,,3,,

l

SUPPLEMENTARY SHEET

030-19521

>

,

I

>

l

Amendment No. 11

h

1

>

i

l

CONDITIONS

I

li

l

(continued)

l

8

l

The licensee shall maintain for inspection by the Comission copies of the

y

g

I

written permission specified in A. above and of the license (s) specified in B.

I

and C. above for a period of 5 years from the date permission is granted under

i

>

4

A. above.

4

i

l 14. The licensee is authorized to hold radioactive material with a physical

l

q

half-life of less than 65 days >for'decayLin'-storage before disposal in ordinary

n

'

i

~

p

q

trash provided:

c'

,-

I

q

,N,

-

4

A.

Radioactive waste to!be disposed of in this manner shall be held for decay

I'

l

a minimum of ten (10) half-lives.

~

l

q

B.

Prior to dispos'al as"normal waste, radioactive waste shal.1 be surveyed to

In

s

n

4

determine that(its radioactivity cannot be distinguished from background.

p

4

All radiation labels shall'be removed;or obliterated.

>

-

4

i

>

C.

Generator columns shall be segregated so that they may be' monitored

l

separately to ensure' decay to background levels prior to disposal.

p

g

q

,n

.

F

'

-

R 15. The licensee may transport licensed material in accordance with the provisions

>

k

4

of 10 CFR Part 71,7"Packaging and Transportation of Radioactive = Material".

i

4

.

jlm

l16. Except as specifically provided otherwise in th'if license, the licensee shall

l(

'

g

conduct its program in accordance with the statements, representations, and

lp

q

procedures contained in'the documents including any enclo;ures, listed below.

Ip:

4

The Nuclear Regulatory Comission's regulations shall govern unless the

l>

f

statements, representations /and procedures in the licensee's application and

lh

g

correspondence are more restrictive than the regulations.

f

A. Application dated December 17, 1986

"

I;

l>p

g

B. Model ALARA Program contained in Appendix 0

>

4

of Regulatory Guide 10.8 (Rev. 1)

j{

.

ji

C. Letter dated September 25, 1987

f

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

>

f'

original signed by B. A. Riedlinger

>

lDateOctober 15, 1987

By

>

k

Beth A. Riedlinger

>

l

HealthPhysicist(Licensing)

h

l

Nuclear Materials Safety Section

p

{k

Region V

p

I

p

-

A

ik)

!>

,>

.. ..- _ _ _.__ _ _ _ _ ..__ 7j

_

>j

_

_--a

ML20155H757

Text

Navigation menu

Search